Insights into the pathogenesis of chronic heart failure: Immune activation and cachexia

Stefan D. Anker, Mathias Rauchhaus

Research output: Contribution to journalArticle

Abstract

Body wasting, ie, cardiac cachexia, is a complication of chronic heart failure (CHF). The authors have suggested that cardiac cachexia should be diagnosed when nonedematous weight loss of more than 7.5% of the premorbid normal weight occurs over a time period of more than 6 months. In an unselected CHF outpatient population, 16% of patients were found to be cachectic. The cachectic state is predictive of poor survival independently of age, functional class, ejection fraction, and exercise capacity. Patients with cardiac cachexia suffer from a general loss of fat, lean, and bone tissue. Cachectic CHF patients are weaker and fatigue earlier. The pathophysiologic causes of body wasting in patients with CHF remain unclear, but initial studies have suggested that humoral neuroendocrine and immunologic abnormalities may be of importance. Cachectic CHF patients show increased plasma levels of catecholamines, cortisol, and aldosterone. Several studies have shown that cardiac cachexia is linked to increased plasma levels of tumor necrosis factor α. The degree of body wasting is strongly correlated with neurohormonal and immune abnormalities. Some investigators have suggested that endotoxin may be important in triggering immune activation in CHF patients. Available studies suggest that cardiac cachexia is a multifactorial neuroendocrine and immunologic disorder that carries a poor prognosis. A complex catabolic-anabolic imbalance in different body systems may cause body wasting in patients with CHF.

Original languageEnglish
Pages (from-to)211-216
Number of pages6
JournalCurrent Opinion in Cardiology
Volume14
Issue number3
DOIs
Publication statusPublished - 1999

Fingerprint

Cachexia
Heart Failure
Aldosterone
Endotoxins
Catecholamines
Fatigue
Hydrocortisone
Weight Loss
Outpatients
Tumor Necrosis Factor-alpha
Fats
Research Personnel
Exercise
Weights and Measures
Bone and Bones
Survival
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Insights into the pathogenesis of chronic heart failure : Immune activation and cachexia. / Anker, Stefan D.; Rauchhaus, Mathias.

In: Current Opinion in Cardiology, Vol. 14, No. 3, 1999, p. 211-216.

Research output: Contribution to journalArticle

Anker, Stefan D. ; Rauchhaus, Mathias. / Insights into the pathogenesis of chronic heart failure : Immune activation and cachexia. In: Current Opinion in Cardiology. 1999 ; Vol. 14, No. 3. pp. 211-216.
@article{34261ae817034bc193a37cedb8637493,
title = "Insights into the pathogenesis of chronic heart failure: Immune activation and cachexia",
abstract = "Body wasting, ie, cardiac cachexia, is a complication of chronic heart failure (CHF). The authors have suggested that cardiac cachexia should be diagnosed when nonedematous weight loss of more than 7.5{\%} of the premorbid normal weight occurs over a time period of more than 6 months. In an unselected CHF outpatient population, 16{\%} of patients were found to be cachectic. The cachectic state is predictive of poor survival independently of age, functional class, ejection fraction, and exercise capacity. Patients with cardiac cachexia suffer from a general loss of fat, lean, and bone tissue. Cachectic CHF patients are weaker and fatigue earlier. The pathophysiologic causes of body wasting in patients with CHF remain unclear, but initial studies have suggested that humoral neuroendocrine and immunologic abnormalities may be of importance. Cachectic CHF patients show increased plasma levels of catecholamines, cortisol, and aldosterone. Several studies have shown that cardiac cachexia is linked to increased plasma levels of tumor necrosis factor α. The degree of body wasting is strongly correlated with neurohormonal and immune abnormalities. Some investigators have suggested that endotoxin may be important in triggering immune activation in CHF patients. Available studies suggest that cardiac cachexia is a multifactorial neuroendocrine and immunologic disorder that carries a poor prognosis. A complex catabolic-anabolic imbalance in different body systems may cause body wasting in patients with CHF.",
author = "Anker, {Stefan D.} and Mathias Rauchhaus",
year = "1999",
doi = "10.1097/00001573-199905000-00004",
language = "English",
volume = "14",
pages = "211--216",
journal = "Current Opinion in Cardiology",
issn = "0268-4705",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Insights into the pathogenesis of chronic heart failure

T2 - Immune activation and cachexia

AU - Anker, Stefan D.

AU - Rauchhaus, Mathias

PY - 1999

Y1 - 1999

N2 - Body wasting, ie, cardiac cachexia, is a complication of chronic heart failure (CHF). The authors have suggested that cardiac cachexia should be diagnosed when nonedematous weight loss of more than 7.5% of the premorbid normal weight occurs over a time period of more than 6 months. In an unselected CHF outpatient population, 16% of patients were found to be cachectic. The cachectic state is predictive of poor survival independently of age, functional class, ejection fraction, and exercise capacity. Patients with cardiac cachexia suffer from a general loss of fat, lean, and bone tissue. Cachectic CHF patients are weaker and fatigue earlier. The pathophysiologic causes of body wasting in patients with CHF remain unclear, but initial studies have suggested that humoral neuroendocrine and immunologic abnormalities may be of importance. Cachectic CHF patients show increased plasma levels of catecholamines, cortisol, and aldosterone. Several studies have shown that cardiac cachexia is linked to increased plasma levels of tumor necrosis factor α. The degree of body wasting is strongly correlated with neurohormonal and immune abnormalities. Some investigators have suggested that endotoxin may be important in triggering immune activation in CHF patients. Available studies suggest that cardiac cachexia is a multifactorial neuroendocrine and immunologic disorder that carries a poor prognosis. A complex catabolic-anabolic imbalance in different body systems may cause body wasting in patients with CHF.

AB - Body wasting, ie, cardiac cachexia, is a complication of chronic heart failure (CHF). The authors have suggested that cardiac cachexia should be diagnosed when nonedematous weight loss of more than 7.5% of the premorbid normal weight occurs over a time period of more than 6 months. In an unselected CHF outpatient population, 16% of patients were found to be cachectic. The cachectic state is predictive of poor survival independently of age, functional class, ejection fraction, and exercise capacity. Patients with cardiac cachexia suffer from a general loss of fat, lean, and bone tissue. Cachectic CHF patients are weaker and fatigue earlier. The pathophysiologic causes of body wasting in patients with CHF remain unclear, but initial studies have suggested that humoral neuroendocrine and immunologic abnormalities may be of importance. Cachectic CHF patients show increased plasma levels of catecholamines, cortisol, and aldosterone. Several studies have shown that cardiac cachexia is linked to increased plasma levels of tumor necrosis factor α. The degree of body wasting is strongly correlated with neurohormonal and immune abnormalities. Some investigators have suggested that endotoxin may be important in triggering immune activation in CHF patients. Available studies suggest that cardiac cachexia is a multifactorial neuroendocrine and immunologic disorder that carries a poor prognosis. A complex catabolic-anabolic imbalance in different body systems may cause body wasting in patients with CHF.

UR - http://www.scopus.com/inward/record.url?scp=0032922755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032922755&partnerID=8YFLogxK

U2 - 10.1097/00001573-199905000-00004

DO - 10.1097/00001573-199905000-00004

M3 - Article

C2 - 10358792

AN - SCOPUS:0032922755

VL - 14

SP - 211

EP - 216

JO - Current Opinion in Cardiology

JF - Current Opinion in Cardiology

SN - 0268-4705

IS - 3

ER -